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Abstract: Despite the incidence and prevalence of urothelial bladder cancer (UBC), few advances
in treatment and diagnosis have been made in recent years. In this review, we discuss potential
biomarker candidates: the tropomyosin family of genes, encoded by four loci in the human genome.
The expression of these genes is tissue-specific. Tropomyosins are responsible for diverse cellular
roles, most notably based upon their interplay with actin to maintain cellular processes, integrity and
structure. Tropomyosins exhibit a large variety of splice forms, and altered isoform expression levels
have been associated with cancer, including UBC. Notably, tropomyosin isoforms are detectable
in urine, offering the potential for non-invasive diagnosis and risk-stratification. This review
collates the basic knowledge on tropomyosin and its isoforms, and discusses their relationships
with cancer-related phenomena, most specifically in UBC.
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1. Introduction
Each year, circa 100,000 patients in the UK undergo investigation for haematuria, the most
common symptom of urothelial bladder cancer (UBC). Around 10% of these patients are subsequently
diagnosed with UBC [1], of which 75–80% will have non-muscle-invasive disease (NMIBC: stages
Ta/T1/Tis) [2]. The remaining 20–25% of patients are diagnosed with muscle-invasive disease (MIBC:
stages T2+) following transurethral resection of bladder tumour (TURBT), and undergo further staging
investigations before receiving definitive treatment.
For NMIBC patients, long-term cystoscopic surveillance is the mainstay of management following
initial transurethral resection (TURBT) and adjuvant intravesical therapy [3]. Cystoscopy is expensive,
invasive, uncomfortable, and carries morbidity [4]. Consequently, bladder cancer is one of the most
expensive malignancies to manage on a per-patient basis from diagnosis to death, the majority of which
is attributable to the long-term treatment and surveillance of NMIBC [5]. Furthermore, significant
patient burden and healthcare costs are incurred by the investigation of patients with haematuria, over
80% of whom are subsequently diagnosed with non-malignant conditions or no abnormality [1].
The development of accurate urinary biomarkers for the non-invasive detection of UBC could
transform patient pathways by reducing reliance on cystoscopy, which is burdensome for patients
and expensive for healthcare providers [6]. Hence, non-invasive diagnosis is a key unmet need for
UBC [7], and has become a global research challenge. A number of commercial biomarkers exist and,
to date, six have been approved by the FDA for the detection and surveillance of UBC (NMP22, NMP22
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BladderChek Test, BTA TRAK, BTA Stat, UroVysion® FISH and ImmunoCyt). However, none have
been accepted into routine clinical practice due to poor performance and/or poor evidence [3,8,9].
Notably, patients require tests that are at least as accurate as cystoscopy [10]. However, cystoscopy
itself is not infallible: sensitivity has been estimated at 85%, with 87% specificity [6,11] (and it is highly
operator-dependent). Thus, as a viable alternative to cystoscopy for patients and healthcare providers
alike, non-invasive urinary biomarkers need to match or exceed the sensitivity and specificity of
conventional flexible cystoscopy, ideally with utility to also risk-stratify patients above and beyond
conventional clinico-pathological tools [3]. This review focuses on the potential use of tropomyosin
(TPM) in the detection and stratification of bladder cancer. TPM performs isoform-specific functions
within normal cells of the urothelium, and alteration in the isoform expression and concomitant
spliceform switching can be observed in the event of bladder carcinogenesis, as will be discussed later
in Section 4.
2. Tropomyosin
2.1. Background and Diversity
Tropomyosin was first identified as a myofibrillar structural protein, involved in contractile
function within skeletal and cardiac muscle [12]. TPM is a key regulator in the excitation–contraction
coupling mechanism within muscle cells that allows synchronous movements of the myosin heads
with the corresponding actin filaments. Though tropomyosins are largely seen to be part of muscle
cells, their functions are not limited to muscle cells alone. TPMs have been found in all living cells,
including yeast, with the exception of plants and bacteria [13]. TPMs form coiled-coil actin-binding
dimers involved in the structural and functional integrity of both the thin-filaments in muscle and the
actin cytoskeleton in non-muscle cells. They form an integral component in the regulation of cellular
viability and differentiation, and any alterations in gene expression impact cell morphogenesis [13].
The tropomyosin genes thus influence cellular motility, cell–cell adhesion and extracellular interactions,
as seen in their contribution to cancer cell metastasis via cell proliferation, migration and invasion [13].
As we see in Sections 5 and 8, isoform usage and expression levels change during carcinogenesis in
tissue-specific patterns, highlighting the complexity of TPM gene and splicing regulation.
The biodiversity of the gene products is achieved by the expression of multiple isoforms and was
revealed in greater detail following the publication of the complete human genome [14]. The human
genome contains only four genes of the tropomyosin family, however, by the use of differential
promoter sequences and splicing events, more than 40 different tropomyosin isoforms are generated
from these four genes. The four loci are named α-, β-, γ- and δ- genes (formally known as TPM1, TPM2,
TPM3 and TPM4, respectively). The gene loci are widely dispersed and are not interlinked: 15q22, 9p13,
1q22 and 19p13 [15]. Historically, research on the usage of tropomyosin isoforms for tissue-specific
functions generated a myriad of names that were used interchangeably. To mitigate the resulting
naming confusion, an agreed nomenclature has been devised and approved by the National Centre
for Biotechnology Information (NCBI) to identify the particular isoform in question [16]. For instance,
the TPM1 gene encodes for the Tm2 isoform, hence named as Tpm1.2. For the purpose of clarity, this
article will use the approved latest version of tropomyosin nomenclature (Table 1).
TPM isoforms are commonly divided into two categories on the basis of their molecular weight:
high-molecular weight (HMW) tropomyosins are ~284 amino acids in length (32–40 kDa) and
low-molecular weight (LMW) TPMs are ~248 amino acids in length (28–33 kDa) [17]. Of the four TPM
genes, three give rise to both LMW and HMW isoforms (TPM1, 3 and 4), whereas TPM2 encodes
only HMW isoforms [17]. An overview of common isoforms and their molecular weight classification
can be found in Table 1. All TPM genes have an initial transcriptional promoter at exon 1a. The
LMW TPMs result from alternative promoter usage, with the possibility of using either exon 1a or
an internal promoter found in an intron upstream of exon 1b [17]. The numbering of the exons is
possible because the members of the gene family share sequence similarity at the individual exon level.
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Variable expression levels of LMW isoforms result from the ability of the genes to incorporate exon 6a
internal splice variants: promoters at exon 9a, 9b, 9c and 9d from TPM1; exon 9a and 9b from TPM3;
and exon 9a from TPM4 [17].
Table 1. Distribution of molecular weight over well-characterized tropomyosin (TPM) isoforms and
genes. HMW: high molecular weight; LMW: low molecular weight.
Tropomyosin
Gene
TPM Isoforms
Common (Old) Name
TPM
Nomenclature
Size
(HMW/LMW)
Molecular Weight
(kDa)
TPM1
Tm2
Tm3
Tm5a
Tm5b
Tm6
Tpm 1.6
Tpm 1.7
Tpm 1.8
Tpm 1.9
Tpm 1.4
HMW
HMW
LMW
LMW
HMW
36
34
30
30
40
TPM2 Tm1 Tpm 2.1 HMW 38
TPM3 Tm5NM1 Tpm 3.1 LMW 30
TPM4 Tm4.1Tm4
Tpm 4.1
Tpm 4.2
HMW
LMW 30
2.2. Function
Within non-muscle cells, actin forms an arbitrary pattern of intracellular cytoskeleton bound
to structural proteins that play an important role in multiple cellular processes as well as in
the maintenance of cell structure and integrity. TPMs are involved in the regulation of actin’s
interaction with binding proteins, as well as in the stabilization of the actin filament and its assembly
kinetics [18–20]. Stable polymerized actin filaments are also referred to as stress fibres. The complexity
of tropomyosin isoforms points to numerous tissue-specific and cell-specific functions. TPMs regulate
actin polymerization through their protective ability, decreasing the rate by which actin is removed
from the pointed end of the filament, which is prone to depolymerisation [20]. The relative binding
capabilities of TPMs with actin are inversely proportional to their molecular weight. HMW isoforms
have a 3-fold increased propensity to co-localize with actin filaments (as seen in skeletal and cardiac
muscle) compared to LMW isoforms. Conversely, LMW TPMs are present in peripheral ruffles, stress
fibres, or diffuse dot locations within the cell [18]. For example, Tpm3.1 has a strong affinity for
actin that prevents Arp2/3-dependent branching and severing of stable actin polymers by proteins
such as ADF/cofilin [20]. Disruption of the stress fibres can impact cell morphogenesis, motility and
stability—phenomena observed in early tumourigenesis.
Conversely, cofilin in abundance may act synergistically with specific TPM isoforms and increase
actin dynamics in normal and transformed cells [21]. Gelsolin is also known to compete with TPM in
binding to actin through depolymerisation, severing and branching of actin filaments that can lead
to formation of lamellipodia. This activity is regulated by isoform-specific TPMs that are associated
with the target filament [22]. It can be deduced that TPMs limit lamellipodia formation and cellular
migration/invasion. Myosin-motor activity is regulated by TPM in an isoform-specific manner. Fascin
is another actin-bundling protein that works synergistically with Tpm1.7, and is found in abundance in
filopodia [23]. It is feasible that the actin-filament-binding abilities of TPMs relative to their molecular
weights could provide a route to the discovery of prognostic biomarkers.
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2.3. Splice Form Variants
Although over 40 different TPM isoforms have been identified to date, it should be borne in mind
how many of these isoforms actually give rise to functional protein molecules. According to the latest
gene annotation information available (Ensembl Release 94, GRCh38) supported by RNA-sequencing
data, the gene products are:
1. TPM1—19 protein-coding isoforms and 6 nonsense-mediated decay (NMD) candidates
2. TPM2—8 protein-coding isoforms
3. TPM3—12 protein-coding and 2 NMD candidates
4. TPM4—14 protein-coding and 5 NMD candidates
Amongst the protein-coding isoforms, the amount of supporting evidence varies (supported
by expressed sequence tags or RNA-sequencing data) and their expression is postulated to be
tissue-specific [24]. In addition to the tissue-level heterogeneity of TPM isoforms, sub-cellular
localization is also utilized to compartmentalize cellular roles. A large number of studies have
reported mechanisms by which TPM genes generate isoform diversity [13]: for example, TPM1 codes
Tpm1.6 and Tpm1.7 (Tm2 and Tm3, respectively), yet also produces differential isoforms of Tpm1.8
and Tpm1.9 (Tm5a and Tm5b) via alternative splicing events. These events are tissue-specific and
have distinct functions in their destined locations [25].
3. TPM Expression and Signalling Pathways in Cancer
The interactions of tropomyosin isoforms with their actin-binding proteins influences the
functional fate of individual cells, maintained by the signalling pathways responsible for apoptosis,
and hence the regulation of cell cycle and prevention of tumour growth in vivo. Alterations of TPM
expression are a key feature of the phenotypic changes of transformed cells. Oncogene-mediated
alteration within signalling pathways affects TPM expression levels. Mutagenic alterations mediated
by Smad and MAPK pathways play a pivotal role in development of carcinogenesis in UBC [26].
The transforming growth factor beta (TGF-β) family of cytokines play important roles as tumour
suppressors by inducing pro-apoptotic pathways in normal epithelial cells [27]. In the early stages of
tumorigenesis in most epithelial cells, alterations within TGF-β regulation in transformed cells cause a
shift towards the progression of disease, as a result of immunosuppression and pro-angiogenesis [28].
TGF-β interacts with TPM by upregulating the expression of TPM1 and TPM2, encoding for the HMW
isoforms Tpm2.1, 1.6, 1.7 and 1.4 (Tm1, 2, 3 and 6 respectively). These isoforms are necessary for the
formation of stress fibres, reducing cell motility and migration. Activation of the Ras-ERK pathway
inhibits the TGF-β induction of stress fibres by suppressing the expression of tropomyosin, leading to
a more motile and invasive phenotype [26]. Additional pathways identified in the propagation of UBC
include members of the p53/Rb and RTK/RAS/P13K pathway. Notably, genetic alterations within
Notch and Hedgehog signalling pathways are responsible for tumour progression [29]. These cellular
pathways either directly or indirectly inhibit TPM gene expression, thereby decreasing the formation
of TPM–actin polymers, destabilizing cellular stability, and promoting motility and spread (Figure 1).
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4. Tropomyosin and Urothelial Bladder Cancer
4.1. Potential Molecular Mechanisms of Regulation of TPM Isoform Usage
In 2000, Hanahan and Weinberg described the six “hallmarks of cancer” that we have previously
described in the context of UBC carcinogenesis [30–32]. A revised version in 2011 added two
more important mechanisms—“reprogramming of energy metabolism” and “evading immune
destruction”—that sustain tumour progression and disease [33]. UBC tumourigenesis is complex and
multifactorial, and the specific molecular processes are beyond the scope of this review. Hence, we
will focus on the contribution and effects of TPMs within these processes.
Normal urothelial cells contain an abundance of HMW TPM isoforms of the TPM1 and TPM2
genes [34]. These (Tpm1.6 and Tpm1.7) are incorporated within actin bundles to stabilize stress fibre
formation, maintain cellular integrity and prevent motility [20]. In the event of DNA damage, TPM1
rescues transformed cells by acting in conjunction with long non-coding RNA MEG3 (Maternally
expressed gene 3) in inhibiting cell proliferation, causing cell cycle arrest in stage G0/G1 (with
dampening of G2/M), and promoting apoptosis (with upregulation of Bcl2-associated X (BaX) and
caspase-3, and downregulation of Bcl2 and cyclin D1) [35].
Cell–cell adhesion is maintained and monitored in the epithelial zonula adherens. Cell adhesion
and cytokinesis are established by Tpm2.1, and are involved in the process of anoikis (a form of cell
death induced by detachment from the extracellular matrix) [20]. Tpm2.1 expression is similar in both
NMIBC and MIBC. It has been hypothesised that the expression of TPM2 is an early event during
bladder carcinogenesis [34,36]: in the initiation phase of tumorigenesis in UBC, HMW isoforms Tpm1.6
and Tpm2.1 have markedly reduced expression levels [34]. With ongoing transformation incited by
either oncogenes, carcinogens, oncogenic DNA and/or RNA viruses, immunity to antigrowth signals is
achieved. A notable association exists between TPM1, miR-96 (microRNA 96), and the long non-coding
RNA MEG3 (Maternally expressed gene 3), where MEG3 and TPM1 are downregulated and miR-96
levels are upregulated. Regulation of isoform-specific expression by micro-RNA is generated by
targeting the FOXQ1 gene, which induces epithelial–mesenchymal transition (EMT, the process by
which the epithelial cells acquire characteristics of mesenchymal cells), promoting the progression
of disease [35]. Suppression of TPM1 is a hallmark of EMT: loss of polarity and disassembly of cell
junctions as a precursor to invasion and metastasis.
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In UBC, the MAPK pathway promotes limitless replicative capability, resulting in uncontrolled
cellular proliferation, growth and invasion [31]. MAPK activation induces TPM isoform switching
due to alternative promotor usage and maintains the ability of transformed cells to express high levels
of Tpm3.1 [35]. Tpm3.1 is an important TPM isoform associated with multiple cancers, including
UBC, and is involved in a multitude of cellular processes. Tpm3.1 regulates the uptake of glucose
within the adipose cells via the insulin-stimulated GLUT4 transporter in the plasma membrane [37],
generation of stress fibres, excitation–contraction coupling, and MEK/ERK-mediated regulation
of cell proliferation [20]. Tpm3.1 also results in the failure of MyoIb (unconventional myosin Ib,
a key intracellular organelle transporter) to not recognize actin filaments, destabilizing the cell’s
structural integrity [38]. Furthermore, degradation of matrix and invasion into the extracellular
matrix (ECM) is propagated by the formation of lamellipodia, resulting from the overexpression
of LMW isoforms [35,39]. These transformed cells eventually invade and escape from the ECM
to metastasize to distant sites. Through the ectopic expression of isoforms Tpm1.6 and Tpm2.1 in
cancerous cells, sustainability is maintained in a simulated normal-like morphology, which inhibits
anchorage-independent growth (Table 2) [34].
As outlined above, in conjunction with other members of the cytoskeletal machinery, TPMs
can mediate differential and alternative cellular capabilities for malignant transformation and
invasion into (and escape from) the ECM. Furthermore, due to their many isoforms and tissue- and
compartment-specific regulation, TPMs have the potential to support malignant transformation simply
by aberrant regulation. This aberrant regulation may be mediated through alternative transcription
factor binding site usage, as indicated by the aforementioned work in a non-cancerous cell-line by
Savill et al. [17].
Table 2. TPM isoform usage in urothelial bladder carcinogenesis. EMT: epithelial–mesenchymal transition.
Bladder Cancer Stage Hallmark Process TPM Involvement
Normal Self-sufficiency ingrowth signals
Normal expression levels of
TPM genes
Tpm 1.6 and Tpm
1.7—formation of stress fibres,
cell stability, reduced motility
Suppression Insensitivity to growthinhibitory signals
Cell-cycle arrest in G0/G1 if
proliferating too much
TPM1 + MEG3 causes apoptosis
by upregulation of Bcl2 and
caspase3
TPM1—acts as tumour
suppressor
Initiation Evasion of programmedcell death
Decreased expression of TPM1
and TPM2
TPM1 is downregulated due to
increased micro-RNA 96
(suppression lost)
Loss of TPM1—EMT
Tpm 2.1—responsible for
anoikis, maintains cell–cell
adhesion
Non-invasive Limitless replicativepotential
Mutagenic MAPK signalling
activated
Tpm3.1—cellular growth,
proliferation and motility
Invasive Sustained angiogenesis
Invasion into extracellular
matrix (ECM)
Angiogenesis stimulated by
concurrent pathways
LMW TPMs—formation of
lamellipodia, increased cell
motility and morphogenesis
Metastasis Tissue invasion anddeath
Breakthrough ECM with distant
spread
LMW isoforms of TPM3 and
TPM4—Cancer cell survival,
focal adhesion,
MEK/ERK-mediated
proliferation
Evading immune
destruction
Ectopic expression of TPM1 and
TPM2
Continued uninhibited
anchorage-independent growth
4.2. Isoform Switching Due to Alternative Promoter Usage
Using the UCSC Genome Browser and the ENCODE regulatory tracks (histone marks and
transcription factor binding sites), we performed an initial assessment of potential mechanisms for
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tropomyosin dysregulation by alternative transcriptional activation. These data are preliminary, since
the underlying datasets are incomplete (the cell lines, the epigenetic marks, and transcription factors
available have been chosen by the ENCODE consortium selectively, and do not represent all cell and
tissue types). Thus, our observations should be evaluated further in the context of the cell-line and
tissue type, and ultimately integrated with data from UBC. However, with these caveats, an initial
inspection of the TPM gene family isoforms results in the following observations:
• TPM1 has differential presence of RXRA (retinoid X receptor alpha) transcription factor
binding-site (TFBS) for its LMW isoforms, as observed in two cell lines: H1-hESC (a human
embryonic stem cell line) and HepG2 (a human liver cancer cell line).
• TPM3 and TPM4 have differential presence of the E2F1 TFBS for its LMW isoforms, as observed
in the HeLa (cervical cancer) and MCF-7 (a breast cancer cell line) cell lines.
RXRA has been implicated in UBC [40] and E2F1 has been reported as an independent risk factor
for UBC prognosis [41]. Given the differential presence of established cancer-related TFBS in alternative
TPM promoters, and previous observations in different cancer settings, expression differences in TPM
genes should be studied at the isoform level.
5. TPM as a Marker for Cancer Prognosis
5.1. UBC
HMW isoforms of TPMs bind tightly to actin polymers, stabilizing cellular structure and building
a network of stress fibres to facilitate anchorage-dependent growth. The reduction of these isoforms
and replacement by LMW isoforms—as evidenced in some malignant cells—promotes cell mobility and
metastatic spread. Given their functional implications in cancer and cancer progression, TPMs—and
especially TPM isoform expression—may serve as future biomarkers for disease state and prognosis.
For example, decreased TPM1 expression is seen more often in high-grade urothelial carcinoma, MIBC
and metastatic bladder cancer than in low-grade urothelial carcinoma, NMIBC and non-metastatic
bladder cancer [35]. Low expression of TPM1 is related to worse grade and stage, as well as
metastasis [35].
5.2. Other Cancers
Elevated levels of TPM3 expression have been found related to very poor prognosis in glioma [42].
In hepatocellular carcinoma (HCC) cell lines, amplification of TPM3 leads to upregulation of
Snail-mediated EMT and downregulation of E-cadherin which is ultimately responsible for the
migration and invasion of HCC and worse prognosis [43]. In other forms of urinary cancer,
viz. renal cell carcinoma, diminished levels of TPM1 have been found to have strong prognostic
associations—deemed a tumour-suppressor gene in this solid tumour, its association with tumour
size, Fuhrman grade and smoking status has been well established, with an inversely proportional
relationship between TPM1 expression and prognosis [44].
6. Tropomyosins as Gene Fusion Partners
Gene fusion events constitute a class of transcriptional events in which one part of a gene is fused
to a fragment of another, and are observed in many different cancer types [45]. Such fusion events
may be mediated by chromosomal translocations, or may be created at the transcriptomic level by
potential trans-splicing [46] or transcriptional read-through [47]. Although many such fusions may
be passenger events, several fusion events have been found to be recurring driving events in cancer.
A prominent example is the EWS-FLI1 fusion in Ewing sarcoma, which is identified in more than
90% of cases and acts as a tumour-inducing aberrant transcription factor [48]. For TPM3 and TPM4,
recurrent fusion events have been found in a variety of cancers. One of the most frequently-occurring
TPM fusion events is fusion to the ALK (anaplastic lymphoma kinase) gene [47,49,50]. ALK itself
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is a promiscuous fusion partner. Although this tyrosine kinase appears to have its normal activity
in neuronal development, it may hijack 5′ elements from other genes such as TPM3, allowing for
altered (activated) expression and the ability to self-associate, leading to a consecutive activated kinase
domain from the 3′ end of ALK (reviewed in [47]). TPM3 and TPM4 have been found to be frequently
fused to ALK fusions (with 25 (TPM3) and 6 (TPM4) instances, respectively, listed in the curated set of
fusions in the COSMIC database [51]). In a study of kinase fusion events in the TCGA cohort, Stransky
et al. [50] also detected one TPM1–ALK fusion event in the 250 bladder cancer samples investigated.
Another tyrosine kinase found fused with TPM3 is ROS1 (proto-oncogene tyrosine-protein kinase),
found in lung cancer [52] and spitzoid melanomas [53], resulting in a similar change of kinase function
as for ALK. NTRK1 (neurotrophic receptor tyrosine kinase 1) also fuses to TPM3; seen in more than
5% of thyroid cancers, the event again connects the TPM3 5′ end with the NTRK1 kinase domain. In
summary, TPMs can be used by kinases as fusion partners to result in high levels of expression. Future
studies would be necessary to determine if they also interfere with the normal function of the TPM
genes and the associated cellular processes.
7. Detection in Urine
Due to the evidence that TPM isoforms may be prognostic, they might also serve as biomarkers
for disease and disease state. In UBC, it would be especially interesting to investigate if a urinary
diagnostic test based on tropomyosins and their isoforms could be feasible. Such a test could be based
on the quantification of relative isoform usage, which might be more robust against dilution and
admixture of other protein/RNA species. Furthermore, due to their abundance within skeletal and
cardiac muscle as noted earlier, it could be hypothesized that the secretion or release of TPM isoforms
within urinary exosomes could be indicative of breach of the basement membrane and invasion into
and beyond the muscular layer of the bladder wall. Note that microRNA-96 has been reported as
a potential biomarker, detectable in urine [54], which might be a proxy to TPM isoform usage. In
the deep RNA sequencing study of Sin et al. [55], comparing healthy and bladder cancer patients
by differential gene expression in order to detect biomarkers, tropomyosins were not reported to be
significantly differentially expressed between the healthy and the disease state. However, this simply
indicates that the total TPM level stayed similar (differential isoform usage was not investigated). Zhao
et al. created a comprehensive catalogue of proteins detectable by different proteomic approaches
from the pooled urine of 24 healthy volunteers, and detected TPM1, TPM2 and TPM4 [56]. In the same
work, the authors also compiled a database including five recent comprehensive proteomic studies of
urine, in which TPM3 was detected twice, and TPM1 and TPM4 once (excluding their own studies and
vesicle-based studies). Existing evidence shows that TPMs can be detected by mass spectrometry in
urine, but does not provide information on splice form variants, and thus this aspect of biomarker
utility remains uninvestigated.
In addition, RNA sequencing and proteomic research has also been conducted on urinary
exosomes. Using Vesiclepedia [57], we evaluated whether TPMs are, in principle, detectable in
urine samples in such experiments. We found TPM1 and TPM3 in two experiments and TPM4 in three
out of a total 76 human urine experiments, all detected by mass spectrometry. This indicates some
recurrence of TPMs in urinary exosomes. It also illustrates regular inclusion of TPMs in the exosomes
in contrast to most detected genes, which occurred in only one study and might therefore represent a
one-off occurrence.
Aside from urine, the frequency of TPMs is much higher and detectable in cell exosomes and
other biofluids (Figure 2). We conducted the same analysis for microRNA-96 (using the section of
Vesiclepedia for microRNA-targeted experiments) and found hsa_mir96-5p to be more specific to
urine, where it is observed frequently (5 out of 7 experiments). Even though not all the experiments
which report either TPMs or mir96 are in a UBC setting (only one experiment in UBC urine is reported
in Vesiclepedia), the reported evidence indicates, in principle, the detectability in urinary exosomes
by mass spectrometry and microRNA sequencing, respectively. The shortcomings encountered with
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shotgun proteomics may be mitigated in the future by using affinity-capture to enrich for TPMs, the
development of specific bioinformatics approaches to identify specific isoforms and ultimately the use
of targeted mass spectrometry (MRM: multiple reaction monitoring) for isoform-specific peptides.Int. J. Mol. Sci. 2019, 20, x 9 of 14 
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8. Tropomyosin Isoforms in Other Cancers
Although this review focuses on TPM in UBC, we also report findings from other cancers,
highlighting the general importance of tropomyosins in cancer.
8.1. Malignant Breast Epithelial Cells
HMW tropomyosin isoforms of TPM1 and TPM2 are expressed in normal breast epithelial cells
along with the expression of LMW isoforms of TPM1 and TPM4. It has been observed that the
expression of these genes is downregulated in some (although not all) malignant breast cells. An
additional four novel isoforms of the TPM1 gene (that encode TPM isoforms) have been identified
in nine malignant breast epithelial cell lines and are not otherwise expressed in normal adult breast
tissue [58]. The TPM2 isoform has been found markedly upregulated in aggressive forms of breast
cancer with lymph node metastases [58,59], and could potentially serve as a prognostic biomarker.
8.2. Cholangiocarcinoma
It has been demonstrated that levels of TPM1 are downregulated in intrahepatic cholangiocarcinoma
and upregulated in extrahepatic cholangiocarcinoma. TP 1 regulation in this case is regulat d by
tw import nt cellular pathways (i. ., RAS/PI3K/AKT and RAS/MEK/ERK), and via inhibition of
epigenetic mechanisms [60]. These pathw ys lso seem to overlap with UBC and could be targets for
future therapies.
8.3. Prostate Cancer
Alternative splicing events give rise to several isoforms in normal cells and may not be directly
involved i carcinogenesis. However, some i ofo ms do stimulate cellular expansion a d th grow h
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of malignant cells, providing a “tumour microenvironment”. This phenomenon is observed in prostate
cancer where mutagenic pathways cause overexpression of the TPM1 isoform, providing a platform
for distant metastases [61].
8.4. Colon Cancer
The T84 Colon cancer cell line has been used to isolate a novel isoform of Tpm3.12, named TC22,
which has been associated with colonic carcinogenesis. Its presence in benign polyps and increased
expression levels by up to 75% in adenomatous dysplastic cells demonstrates a relationship with colon
cancer [62].
8.5. Oesophageal Cancer
Ras effector regulatory pathways MEK/ERK and PI3K/AKT are compromised in oesophageal
squamous cell carcinoma cell lines, leading to downregulation and decreased expression of TPM1 and
TPM2 [63]. A similar pattern is observed in UBC, where downregulation of HMW TPM isoforms leads
to higher grade and stage and poorer prognosis [35].
9. Discussion and Conclusions
Whilst tropomyosin isoforms have been investigated for decades, their true potential as cancer
biomarkers has not been evaluated to date. Given their complexity of isoforms, as well as tissue-
and cell-specific functions, many findings remain to be discovered. They play an integral role in
combination with the actin cytoskeleton in the maintenance of cell morphology, and alterations in gene
expression may mediate EMT, leading to more aggressive disease and worse survival. With ongoing
technological advances, we suggest that the investigation of tropomyosin isoforms could mediate
further advances in UBC diagnosis and risk stratification. With the limited knowledge currently
available, the detection of novel isoforms remains a challenge. Whether tropomyosin isoforms could
be quantified as protein molecules within urine or genetic alterations within alternative splicing
events of TPM mRNA remains to be uncovered. However, with the availability of genomic data and
experimental validation, we are currently investigating the precise role of this enigmatic protein in the
pathogenesis of UBC.
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